PFO
AXSM icon

Pathstone Family Office’s Axsome Therapeutics AXSM Stock Holding History

Pathstone Family Office’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400
Closed -$2K – 714
2020
Q4 		$2K Buy
+400
New +$29.9K ﹤0.01% 1019

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Pathstone Family Office's AXSM Position: Q1 2023 in Review

Pathstone Family Office sold out of Axsome Therapeutics (AXSM) in Q1 2023, closing a stake of 2,600 shares — an estimated $324K sold.

Pathstone Family Office first reported a position in AXSM in Q1 2020 and held it in 5 quarters. The position peaked at $324K in Q4 2022. 196 funds tracked by Wall St. Rank hold AXSM as of Q1 2023.

  • Pathstone Family Office reported no remaining Axsome Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Pathstone Family Office sold 2,600 Axsome Therapeutics shares in Q1 2023, an estimated $324K.
  • Pathstone Family Office first reported a position in Axsome Therapeutics in Q1 2020 and held it in 5 quarters.
  • Pathstone Family Office's Axsome Therapeutics position peaked at $324K in Q4 2022.
  • 196 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2023.

Based on Pathstone Family Office's 13F filing for Q1 2023, filed 15 May 2023.